Sanofi Free Cash Flow 2012-2026 | SNY
Sanofi annual/quarterly free cash flow history and growth rate from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Sanofi free cash flow for the quarter ending March 31, 2026 was 0.00, a year-over-year.
- Sanofi free cash flow for the twelve months ending March 31, 2026 was , a year-over-year.
- Sanofi annual free cash flow for 2024 was $7.95B, a 10.95% decline from 2023.
- Sanofi annual free cash flow for 2023 was $8.928B, a 13.65% decline from 2022.
- Sanofi annual free cash flow for 2022 was $10.339B, a 4.98% decline from 2021.
| Sanofi Annual Free Cash Flow | |
|---|---|
| 2024 | 7,950.19 |
| 2023 | 8,927.89 |
| 2022 | 10,338.98 |
| 2021 | 10,880.97 |
| 2020 | 7,142.80 |
| 2019 | 8,010.24 |
| 2018 | 6,770.67 |
| 2017 | 6,734.33 |
| 2016 | 6,599.76 |
| 2015 | 6,361.48 |
| 2014 | 8,510.18 |
| 2013 | 7,923.31 |
| 2012 | 8,895.95 |
| 2011 | 10,997.55 |
| Sanofi Quarterly Free Cash Flow | |
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | |
| 2025-06-30 | 2,916.33 |
| 2025-03-31 | 2,204.98 |
| 2024-12-31 | 7,950.19 |
| 2024-09-30 | |
| 2024-06-30 | 155.07 |
| 2024-03-31 | |
| 2023-12-31 | 8,927.89 |
| 2023-09-30 | |
| 2023-06-30 | 3,501.27 |
| 2023-03-31 | |
| 2022-12-31 | 10,338.98 |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-09-30 | |
| 2021-03-31 | |
| 2020-09-30 | |
| 2020-03-31 | |
| 2019-09-30 | |
| 2019-03-31 | |
| 2018-03-31 | |
| 2017-12-31 | 6,734.33 |
| 2017-09-30 | |
| 2017-06-30 | 2,198.20 |
| 2017-03-31 | |
| 2016-12-31 | 6,599.76 |
| 2016-09-30 | |
| 2016-06-30 | 1,645.83 |
| 2016-03-31 | |
| 2015-09-30 | |
| 2015-06-30 | 2,834.08 |
| 2014-06-30 | 2,851.97 |
| 2013-06-30 | 2,095.97 |
| 2012-06-30 | 4,641.78 |
| 2012-03-31 | |
| 2011-12-31 | 10,997.55 |
| 2011-09-30 | |
| 2011-06-30 | 4,523.90 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |